The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice

Journal of Neural Transmission

Volumn 106, Issue 2, 1999, Pages 123-129

  Carlsson, M L ^a,b   Martin, P ^a   Nilsson, M ^a   Sorensen, S M ^a   Carlsson, A ^a   Waters, S ^a   Waters, N ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Box 431 ^*  (Sweden)

Author keywords

d amphetamine; Glutamate; M100907; MK 801; Schizophrenia; Serotonin

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPHETAMINE; DIZOCILPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN 2A ANTAGONIST; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

AMPHETAMINE; ANIMALS; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FLUOROBENZENES; GLUTAMIC ACID; HALOPERIDOL; HYPERKINESIS; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; N-METHYLASPARTATE; PIPERAZINES; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0033048899     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050144     Document Type: Article

References (10)

1. Carlsson ML (1995) The selective 5-HT2A-receptor antagonist MDL100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse- implications for psychosis. J Neural Transm [Gen Sect] 100: 225-237
2. Carlsson ML (1998) Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J Neural Transm 105: 525-535
3. Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129: 79-84
4. Holm ES, Waters N, Hansson L, Carlsson ML (1995) Interactions between central glutamalergic, dopaminergic and serotonergic neurotransmission in the control of locomotor activity. Society for Neuroscience, San Diego, California (Abstract volume 153. 13)
5. Martin P (1998) 5-HT 2 receptor antagonism and antipsychotic drugs: a behavioural and neurochemical study in a rodent hypoglutamatergia model. Thesis, University of Göteborg
6. Martin P, Waters NW, Waters ES, Carlsson A, Carlsson ML (1997) MK-801 hyperlocomotion; differential effects of MDL100907, SDZ PSD-958 and raclopride. Eur J Pharmacol 335: 107-116
7. Maurel Remy S, Bervoets K, Millan MJ (1995) Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280: R9-11
8. Moser PC, Moran PM, Frank RA, Kehne JH (1996) Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behav Brain Res 73: 163-7
9. Schmidt CJ, Kehne JH, Carr AA (1997) MDL 100,907: a selective 5-HT2A receptor antagonist for the treatment of schizophrenia. CNS Drug Rev 3: 49-67
10. Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266: 684-691